Chaib, Selim http://orcid.org/0000-0003-0497-2002
López-Domínguez, José Alberto http://orcid.org/0000-0001-8733-3294
Lalinde-Gutiérrez, Marta http://orcid.org/0000-0002-9858-8775
Prats, Neus
Marin, Ines
Boix, Olga
García-Garijo, Andrea http://orcid.org/0000-0002-7775-0737
Meyer, Kathleen
Muñoz, María Isabel
Aguilera, Mònica http://orcid.org/0000-0003-0763-7947
Mateo, Lidia http://orcid.org/0000-0002-9076-4025
Stephan-Otto Attolini, Camille http://orcid.org/0000-0001-8045-320X
Llanos, Susana http://orcid.org/0000-0002-8555-9326
Pérez-Ramos, Sandra http://orcid.org/0000-0002-3612-4027
Escorihuela, Marta
Al-Shahrour, Fatima http://orcid.org/0000-0003-2373-769X
Cash, Timothy P.
Tchkonia, Tamara http://orcid.org/0000-0003-4623-7145
Kirkland, James L. http://orcid.org/0000-0003-1676-4905
Abad, María http://orcid.org/0000-0002-1462-2498
Gros, Alena http://orcid.org/0000-0002-1207-1880
Arribas, Joaquín http://orcid.org/0000-0002-0504-0664
Serrano, Manuel http://orcid.org/0000-0001-7177-9312
Article History
Received: 14 July 2022
Accepted: 14 December 2023
First Online: 24 January 2024
Competing interests
: M.S. is a shareholder of Senolytic Therapeutics, Life Biosciences, Rejuveron Senescence Therapeutics and Altos Labs. S.C. has received royalties from Rejuveron Senescence Therapeutics. T.P.C. is a shareholder of Rejuveron Senescence Therapeutics. A.G. performs consulting work for Rejuveron Senescence Therapeutics. T.T. and J.L.K. have a financial interest related to this research including patents and pending patents covering senolytic drugs and their uses, which are held by the Mayo Clinic. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with the Mayo Clinic conflict of interest policies. The other authors declare no competing interests. The funders had no role in study design, data collection and analysis, decision to publish or paper preparation.